You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Diagnostic and Management Challenges in Patients With Chronic Migraine

  • Authors: Richard Lipton, MD; Dawn C. Buse, PhD; David Dodick, MD; Rashmi B. Halker Singh, MD
  • CME / ABIM MOC Released: 8/30/2018
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 8/30/2019, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for neurologists, primary care physicians, and obstetricians/gynecologists.

The goal of this activity is to review recent data on the need for improved treatment strategies for patients with chronic migraine, and the role that new and emerging monoclonal antibodies can play in preventing, treating, and minimizing the burden of migraine.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Epidemiology, natural history, and burden of migraine
    • Latest efficacy and tolerability data of chronic migraine prevention therapies in development
  • Have greater competence related to potential application of monoclonal antibodies in migraine prevention


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Richard Lipton, MD

    Professor and Vice Chair
    Department of Neurology
    Albert Einstein College of Medicine
    Director
    Montefiore Headache Center
    New York, New York

    Disclosures

    Disclosure: Richard Lipton, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alder Biopharmaceuticals, Inc.; Allergan, Inc.; Amgen Inc.; Autonomic Technologies, Inc.; Avanir Pharmaceuticals; Biohaven Pharmaceuticals; BioVision Inc.; Boston Scientific; Dr. Reddy's Laboratories; ElectroCore Medical, LLC; eNeura Therapeutics; GlaxoSmithKline; Lilly; Merck & Co., Inc.; Pernix Therapeutics; Pfizer Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals USA; Trigemina, Inc.; Vector Therapeutics Corp.; Vedanta Biosciences, Inc.
    Owns stock, stock options, or bonds from: Biohaven Pharmaceuticals; eNeura Therapeutics

    Dr Lipton does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Lipton does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Faculty

  • Dawn C. Buse, PhD

    Clinical Professor
    Department of Neurology
    Albert Einstein College of Medicine
    New York, New York

    Disclosures

    Disclosure: Dawn Buse, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Allergan, Inc.; Amgen Inc.; Avanir Pharmaceuticals; Lilly; Promius Pharma, LLC; Teva Pharmaceuticals USA
    Served as a speaker or a member of a speakers bureau for: Amgen Inc.
    Received grants for clinical research from: Amgen Inc.

    Dr Buse does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Buse does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • David Dodick, MD

    Professor
    Department of Neurology
    Director, Headache Program
    Mayo Clinic
    Scottsdale, Arizona

    Disclosures

    Disclosure: David Dodick, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Acorda Therapeutics; Alcobra Ltd.; Alder Biopharmaceuticals Inc.; Allergan, Inc.; Amgen Inc.; Autonomic Technologies, Inc.; Biohaven Pharmaceutical; Charleston Laboratories, Inc.; CoLucid Pharmaceuticals, Inc.; ElectroCore Medical, LLC; eNeura Therapeutics; Impel NeuroPharma, Inc.; INSYS Therapeutics, Inc.; Ipsen; Lilly; Magellan Health, Inc; Neurolief Ltd.; Nocira LLC; Novartis Pharmaceuticals Corporation; NuPathe, Inc.; Promius Pharma, LLC; Satsuma Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals USA; Theranica Bio-Electronics Ltd.; Tonix Pharmaceuticals Holding Corp.; Vedanta Biosciences, Inc.; W. L. Gore & Associates, Inc.; Xenon Pharmaceuticals Inc.; ZP Opco, Inc.
    Served as a speaker or a member of a speakers bureau for: Sun Pharmaceutical Industries, Ltd.
    Owns stock, stock options, or bonds from: Aural Analytics; EPIEN Medical, Inc; Healint; Second Opinion Health, Inc.; Theranica Bio-Electronics Ltd.

    Dr Dodick does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Dodick does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Rashmi B. Halker Singh, MD

    Assistant Professor
    Department of Neurology
    Mayo Clinic 
    Scottsdale, Arizona

    Disclosures

    Disclosure: Rashmi Halker Singh, MD, has disclosed no relevant financial relationships.

    Dr Singh does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Singh does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

  • Catherine Friederich Murray, BS

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Catherine Friederich Murray, BS, has disclosed no relevant financial relationships.

  • Shira Berman

    Scientific Director, Medscape LLC

    Disclosures

    Disclosure: Shira Berman has disclosed no relevant financial relationships.

CME Reviewer

  • Esther Nyarko, PharmD

    Associate Clinical CME Director, Medscape, LLC

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Diagnostic and Management Challenges in Patients With Chronic Migraine

processing....

 

  • Diagnostic and Management Challenges in Patients With Chronic Migraine

  • Slide 1.

    Slide 1.

    (Enlarge Slide)

This content has been condensed for improved clarity.

  • Print